Roche’s James Sabry zeroes in on a new pathway for protein degradation — and he’s paying $135M cash for a hot ticket
We don’t know all the details about what exactly is driving Roche BD chief James Sabry this time, but he’s clearly on a preclinical tear …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
